艾珍敦促FDA解除米费普里斯顿的限制, 以改善生殖保健的准入, Hey Jane urges FDA to lift mifepristone restrictions to improve reproductive care access, especially in rural and underserved areas.

纽约的远程医疗服务提供商Hey Jane敦促FDA取消对米费普里斯顿的限制,理由是担心监管障碍限制了获得基本生殖保健的机会,特别是在农村和服务不足的人口中. Hey Jane, a New York-based telehealth provider, has urged the FDA to remove restrictions on mifepristone, citing concerns that regulatory barriers limit access to essential reproductive healthcare, especially for rural and underserved populations. 本组织加入了一个更广泛的联盟,倡导通过远程保健和非医学提供者扩大公平获取药物的机会,强调经批准后使用时的安全和有效性。 The organization joined a broader coalition advocating for expanded, equitable access to the medication through telehealth and non-physician providers, emphasizing its safety and effectiveness when used as approved. 这一评论是FDA正在对米费普里斯顿的监管地位进行审查的一部分. The comment is part of the FDA’s ongoing review of mifepristone’s regulatory status.